1区 · 医学
Article
作者: Watanabe, Takashi  ; Shirai, Fumiyuki  ; Watanabe, Hirofumi  ; Honma, Teruki  ; Sato, Shin  ; Shitara, Eiki  ; Shirouzu, Mikako  ; Mazaki, Yui  ; Muramatsu, Yukiko  ; Yuki, Hitomi  ; Umehara, Takashi  ; Okue, Masayuki  ; Seimiya, Hiroyuki  ; Koda, Yasuko  ; Hirama, Chizuko  ; Kitamura, Kouichi  ; Yoshida, Haruka  ; Kano, Yuko  ; Niwa, Hideaki  ; Yoshida, Minoru  ; Yoshimoto, Nobuko  ; Tsumura, Takeshi  ; Washizuka, Kenichi  ; Yashiroda, Yoko  ; Mizutani, Anna  ; Fukami, Takehiro  ; Abe, Masako  ; Koyama, Hiroo  ; Chikada, Tsubasa  ; Onuki, Tetsuo 
The canonical WNT pathway plays an important role in cancer pathogenesis. Inhibition of poly(ADP-ribose) polymerase catalytic activity of the tankyrases (TNKS/TNKS2) has been reported to reduce the Wnt/β-catenin signal by preventing poly ADP-ribosylation-dependent degradation of AXIN, a negative regulator of Wnt/β-catenin signaling. With the goal of investigating the effects of tankyrase and Wnt pathway inhibition on tumor growth, we set out to find small-molecule inhibitors of TNKS/TNKS2 with suitable drug-like properties. Starting from 1a, a high-throughput screening hit, the spiroindoline derivative 40c (RK-287107) was discovered as a potent TNKS/TNKS2 inhibitor with >7000-fold selectivity against the PARP1 enzyme, which inhibits WNT-responsive TCF reporter activity and proliferation of human colorectal cancer cell line COLO-320DM. RK-287107 also demonstrated dose-dependent tumor growth inhibition in a mouse xenograft model. These observations suggest that RK-287107 is a promising lead compound for the development of novel tankyrase inhibitors as anticancer agents.